![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 4827p CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 8th August 1997 The issuer has made the following alteration to the Cambridge Antibody Technology Group PLC announcement released today. PLEASE NOTE THE FOLLOWING RELEASE REPLACES THE ONE PUT OUT EARLIER. THE COMPOUND THAT HAS RECEIVED APPROVAL IS TGFBeta2 NOT TGFa2 AS IT APPEARED ON THE SCREEN Cambridge Antibody Technology Group plc Approval to start clinical trials for human anti-TGFbeta2 monoclonal antibody Cambridge Antibody Technology Group plc ("CAT") announces that it has received approval from the UK Medicines Control Agency to commence a Phase I/IIa clinical trial with its anti-TGFbeta2 antibody in patients with early proliferative vitreo retinopathy. The antibody will be administered by direct intravitreal injection at the time of surgery. Patient enrolment is expected to commence next month at three major ophthalmology centres in the UK. Up to 45 patients will be enrolled in the trial. The trial is designed as a placebo controlled rising single dose study primarily to establish safety and to identify doses for subsequent efficacy studies. This will be the first clinical trial initiated by CAT. Trials of the human anti TNF monoclonal antibody developed by Knoll (BASF) in conjunction with CAT were initiated by Knoll earlier this year in patients with rheumatoid arthritis. Patient recruitment into that trial is proceeding as planned. Dr David Chiswell, CAT's Chief Executive Officer, said: "The proposed use of the anti-TGFb2 antibody addresses a significant medical need. It is a step forward for CAT to move into the clinical phase of product development, and pleasing to achieve this within the timescale we set at the time of our listing on the London Stock Exchange in March 1997." For further information, please contact: Cambridge Antibody Technology 01763 263233 David Chiswell Chief Executive Officer John Aston Finance Director Ludgate Communications 0171 253 2252 Andrew Nicolls Nicola How Notes to Editors CAT CAT's business is based on a world leading platform technology for the rapid isolation of human monoclonal antibodies. This technology has applications both in the development of antibody-based human therapeutic products and as a drug discovery tool, particularly in the context of functional genomics. TGFbeta2 TGFbeta2 is a multifunctional cytokine that appears in three isoforms in mammals: TGFbeta1, TGFbeta2 and TGFbeta3. In the human eye the TGFbeta2 isoform predominates. Of the many biological activities associated with TGFbeta, much interest has focused on its role in tissue repair mechanisms. TGFbeta induces the deposition of extracellular matrix. Over production of TGFbeta can lead to excessive extracellular matrix production which is the hallmark of tissue fibrosis. Anti TGFbeta2 - opthalmic indications CAT is developing the human anti-TGFbeta2 monoclonal antibody for a number of ophthalmic indications; for the prevention of the recurrence of proliferative vitreo retinopathy ("PVR") following PVR surgery, for the prevention of PVR following surgery for retinal detachment and as an adjunct to glaucoma drainage surgery to prevent fibrosis at the operated site. PVR is characterised by the formation of fibrous tissue in, and in front of, the retina following trauma, retinal detachment, or in the late stages of diabetic retinopathy. There is no approved treatment for PVR. Surgery may be attempted but unfortunately the condition almost inevitably progresses leading to traction on the retina causing it to be pulled from its attachment and thus result in permanent loss of vision or blindness. In North America and Western Europe combined, CAT has estimated that surgery to try to prevent the recurrence of, or to remove, PVR, and/or to re-attach a detached retina is undertaken on 100,000 patients per year. CAT's strategy is first to establish the principle of using anti-TGFbeta2 antibodies in acute indications where a single dose/course of treatment may be sufficient. If this principle is established, further clinical studies will be undertaken to extend their use with the longer term objective of addressing other ophthalmic conditions where fibrosis can lead to permanent blindness. END
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions